Results of an investigators’ Phase II clinical trial in vitamin C have been published by Wiley online in Cancer, a peer-reviewed journal of the American Cancer Society. Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off. Because decreased… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More
News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW. This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer. The… Read More
A new CAR T-cell therapy can target key mutations causing rare blood cancers and leave healthy blood cells unharmed, scientists say. A research effort led by University College London (UCL) and the University of Oxford engineered a CAR T-cell therapy which can reprogramme a patient’s own immune cells… Read More
News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW. This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers. The top stories: Edinburgh team… Read More
The first patient has been dosed in a treatment for ROR1-positive blood cancers. NVG-222 is a bispecific T-cell engager targeting ROR1 and CD3, developed by biotechnology company NovalGen. The drug is the first therapeutic candidate to use NovalGen’s proprietary AutoRegulation technology, an innovation designed to mitigate excessive… Read More
Drug Discovery World speaks to companies at the cutting edge of innovation in blood cancer therapeutics. The prognosis for patients with blood cancers has improved dramatically since the turn of the century. Thanks to an ever-growing array of treatments becoming available, there has been significant… Read More
Cancer Research UK has allocated £2.5 million ($3.4 million) to researchers at the University of York to help transform care for patients diagnosed with blood cancers. The funding is for the world leading Haematological Malignancy Research Network (HMRN), one of the most comprehensive blood cancer research networks in the… Read More
Biotechnology company Amphista Therapeutics has announced its nomination of AMX-883 as its first clinical development candidate for the treatment of acute myeloid leukaemia (AML). AMX-883 is a potent, selective and orally bioavailable degrader of BRD9. Leveraging Amphista’s Eclipsys platform and proprietary Targeted Glue technology, AMX-883 induces the… Read More
Ascentage Pharma’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). It is approved in patients who have previously received at least one systemic therapy including Bruton’s tyrosine… Read More
The latest new trial data presented at the 30th European Hematology Association (EHA) 2025 Congress. Bispecific antibody for diffuse large B-cell lymphoma Genmab shared new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously,… Read More
A fixed-duration regimen of AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for previously untreated chronic lymphocytic leukaemia (CLL). The approval by the European Commission follows the positive opinion of the Committee for Medicinal… Read More
Two of Ascentage Pharma’s drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), an investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. This makes… Read More
Washington University School of Medicine in St Louis has been awarded a five-year $10.8 million grant to further its programmes in leukaemia and other blood cancers. The grant, from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), renews funding for the Specialized Program… Read More
Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More
Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies. In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More
